L. A. Steffensen

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

K. Peris, M. Cork, M. Worm, 2020, The British journal of dermatology.

Patient-oriented measures for phase 3 studies of tralokinumab for treatment of atopic dermatitis (ECZTRA 1, 2 and 3).

J. Silverberg, E. Simpson, A. Wollenberg, 2022, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials.

M. Gooderham, A. Pink, E. Simpson, 2023, American journal of clinical dermatology.